

Hypothyroidism

Osama M. Ahmed¹ and R. G. Ahmed^{2,3}

¹*Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University,*

²*Lab of Comparative Endocrinology, Catholic University, Leuven,*

³*Zoology Department, Faculty of Science, Beni-Suef University,*

^{1,3}*Egypt*

²*Belgium*

1. Introduction

Hypothyroidism is caused by insufficient secretion of thyroid hormones by the thyroid gland or by the complete loss of its function. The share of hypothyroidism among other endocrine diseases is gradually increasing. It is encountered in females more than in males. The idiopathic form of hypothyroidism occurs mainly in females older than 40 years. Hypothyroidism is usually progressive and irreversible. Treatment, however, is nearly always completely successful and allows a patient to live a fully normal life (Potemkin, 1889; Thomas, 2004; Roberts and Ladenson, 2004).

2. History

Hypothyroidism was first diagnosed in the late nineteenth century when doctors observed that surgical removal of the thyroid resulted in the swelling of the hands, face, feet, and tissues around the eyes. The term myxoedema (mucous swelling; myx is the Greek word for mucin and oedema means swelling) was introduced in 1874 by Gull and in 1878 by Ord. On the autopsy of two patients, Ord discovered mucous swelling of the skin and subcutaneous fat and linked these changes with the hypofunction or atrophy of the thyroid gland. The disorder arising from surgical removal of the thyroid gland (cachexia strumipriva) was described in 1882 by Reverdin of Geneva and in 1883 by Kocher of Berne. After Gull's description, myxoedema aroused enormous interest, and in 1883 the Clinical Society of London appointed a committee to study the disease and report its findings. The committee's report, published in 1888, contains a significant portion of what is known today about the clinical and pathologic aspects of myxoedema (Wiersinga, 2010).

3. Causes and incidence

Many permanent or temporary conditions can reduce thyroid hormone secretion and cause hypothyroidism. About 95% of hypothyroidism cases occur from problems that start in the thyroid gland. In such cases, the disorder is called primary hypothyroidism (Potemkin, 1889). Secondary and tertiary hypothyroidism is caused by disorders of the pituitary gland and hypothalamus respectively (Lania et al., 2008). Only 5% of

hypothyroid cases suffer from secondary and tertiary hypothyroidism (Potemkin, 1889). The two most common causes of primary hypothyroidism are (1) Hashimoto's thyroiditis which is an autoimmune condition and (2) overtreatment of hyperthyroidism (an overactive thyroid) (Simon, 2006; Aminoff, 2007; Elizabeth and Agabegi, 2008). Primary hypothyroidism may also occur as a result of insufficient introduction of iodine into body (endemic goiter). In iodine-replete communities, the prevalence of spontaneous hypothyroidism is between 1 % and 2 %, and it is more common in older women and ten times more common in women than in men (Vanderpump, 2005 and 2009). Radioiodine therapy may lead to hypothyroidism (Potemkin, 1989). Primary hypothyroidism may also occur as a result of hereditary defects in the biosynthesis of thyroid hormones (due to defect in the accumulation of iodine by the thyroid gland or defect in the transformation of monoiodotyrosine and diiodotyrosines into triiodothyronine and thyroxine) or may be caused by hypoplasia and plasia of the thyroid gland as a result of its embryonic developmental defect, degenerative changes, total or subtotal thyroidectomy (Potemkin, 1889). Hypothalamic and pituitary hypothyroidism, or central hypothyroidism results from a failure of the mechanisms that stimulate thyroid-stimulating hormone (TSH) and TSH releasing hormone (TRH) synthesis, secretion, and biologic action (Thomas, 2004). The most prevalent cause of central hypothyroidism, including secondary and tertiary subtypes, is a defective development of the pituitary gland or hypothalamus leading to multiple pituitary hormone deficiencies, while defects of pituitary and hypothalamic peptides and their receptors only rarely have been identified as the cause of central congenital hypothyroidism (Grueters et al., 2002; Ahmed et al., 2008).

Type	Origin	Description
Primary	Thyroid gland	The most common forms include Hashimoto's thyroiditis (an autoimmune disease) and radioiodine therapy for hyperthyroidism.
Secondary	Pituitary gland	It occurs if the pituitary gland does not create enough thyroid-stimulating hormone (TSH) to induce the thyroid gland to produce enough thyroxine and triiodothyronine. Although not every case of secondary hypothyroidism has a clear-cut cause, it is usually caused by damage to the pituitary gland, as by a tumor, radiation, or surgery. Secondary hypothyroidism accounts for less than 5% or 10% of hypothyroidism cases.
Tertiary	Hypothalamus	It results when the hypothalamus fails to produce sufficient thyrotropin-releasing hormone (TRH). TRH prompts the pituitary gland to produce thyroid-stimulating hormone (TSH). Hence may also be termed hypothalamic-pituitary-axis hypothyroidism. It accounts for less than 5% of hypothyroidism cases.

Table 1. Classification of hypothyroidism according to the origin of cause (Simon, 2006; Aminoff, 2007; Elizabeth and Agabegi, 2008).

4. Grades of hypothyroidism

Hypothyroidism ranges from very mild states in which biochemical abnormalities are present but the individual hardly notices symptoms and signs of thyroid hormone deficiency, to very severe conditions in which the danger exists to slide down into a life-threatening myxoedema coma. In the development of primary hypothyroidism, the transition from the euthyroid to the hypothyroid state is first detected by a slightly elevated serum TSH, caused by a minor decrease in thyroidal secretion of T4 which doesn't give rise to subnormal serum T4 concentrations. The reason for maintaining T4 values within the reference range is the exquisite sensitivity of the pituitary thyrotroph for even very small decreases of serum T4, as exemplified by the log-linear relationship between serum TSH and serum FT4. A further decline in T4 secretion results in serum T4 values below the lower normal limit and even higher TSH values, but serum T3 concentrations remain within the reference range. It is only in the last stage that subnormal serum T3 concentrations are found, when serum T4 has fallen to really very low values associated with markedly elevated serum TSH concentrations (Figure 1). Hypothyroidism is thus a graded phenomenon, in which the first stage of subclinical hypothyroidism may progress via mild hypothyroidism towards overt hypothyroidism (Table 2) (Reverdin, 1882).




Fig. 1. Individual and median values of thyroid function tests in patients with various grades of hypothyroidism. Discontinuous horizontal lines represent upper limit (TSH) and lower limit (FT₄, T₃) of the normal reference ranges (Wiersinga, 2010).

Grade 1	Subclinical hypothyroidism	TSH +	FT4 N	T3 N(+)
Grade 2	Mild hypothyroidism	TSH +	FT4 -	T3 N
Grade 3	Overt hypothyroidism	TSH +	FT4 -	T3 -
+, above upper normal limit; N, within normal reference range; -, below lower normal limit.				

Table 2. Grades of hypothyroidism (Reverdin, 1882).

Taken together, hypothyroidism can be classified based on its time of onset (congenital or acquired), severity (overt [clinical] or mild [subclinical]), and the level of endocrine aberration (primary or secondary) (Roberts and Ladenson, 2004). Primary hypothyroidism follows a dysfunction of the thyroid gland itself, whereas secondary and tertiary hypothyroidism results from either defect in the development or dysfunction of pituitary gland and hypothalamus (Grueters et al., 2002; Ahmed et al., 2008).

5. Hypothyroidism and metabolic defects

The thyroid hormones act directly on mitochondria, and thereby control the transformation of the energy derived from oxidations into a form utilizable by the cell. Through their direct actions on mitochondria, the hormones also control indirectly the rate of protein synthesis and thereby the amount of oxidative apparatus in the cell. A rationale for the effects of thyroid hormone excess or deficiency is based upon studies of the mechanism of thyroid hormone action. In hypothyroidism, slow fuel consumption leads to a low output of utilizable energy. Many of the chemical and physical features of these diseases can be reduced to changes in available energy (Hoch, 1968 & 1988; Harper and Seifert, 2008).

Thyroid dysfunction is characterized by alterations in carbohydrate, lipid and lipoprotein metabolism, consequently changing the concentration and composition of plasma lipoproteins. In hyperthyroid patients, the turnover of low-density-lipoprotein apoprotein is increased, and the plasma cholesterol concentration is decreased. Hypothyroidism in man is associated with an increase in plasma cholesterol, particularly in low-density lipoproteins and often with elevated plasma VLD lipoprotein, and there is a positive correlation with premature atherosclerosis. Although it is known that myxoedemic patients have decreased rates of low-density lipoprotein clearance from the circulation, it is not known with certainty if the elevated concentration of VLD lipoprotein is due to increased secretion by the liver or to decreased clearance by the tissues (Laker and Mayes, 1981).

6. Symptoms associated with hypothyroidism

Hypothyroidism produces many symptoms related to its effects on metabolism. Physical symptoms of hypothyroidism-related reduced metabolic rate include fatigue, slowed heart rate, intolerance to cold temperatures, inhibited sweating and muscle pain. Depression is a key psychological consequence of hypothyroidism and slow metabolism as well. For women, slow metabolism can cause increased menstruation and even impair fertility. Weight gain and metabolic rate are intimately related. A slow metabolism interferes with

the body's ability to burn fat, so those with hypothyroidism often experience weight gain when their condition is not treated properly. Since the metabolism keeps muscles functioning properly and controls body temperature, hypothyroidism can impair these essential metabolic processes. The weight gain can then lead to obesity, which carries its own serious health risks, including for diabetes, heart disease and certain types of cancer. Other side effects include impaired memory, gynecomastia, impaired cognitive function, puffy face, hands and feet, slow heart rate, decreased sense of taste and smell, sluggish reflexes, decreased libido, hair loss, anemia, acute psychosis, elevated serum cholesterol, difficulty swallowing, shortness of breath, recurrent hypoglycemia, increased need for sleep, irritability, yellowing of the skin due to the failure of the body to convert beta-carotene to vitamin A, and impaired renal function (Onputtha, 2010).

Hypothyroidism is frequently accompanied by diminished cognition, slow thought process, slow motor function, and drowsiness (Bunevičius and Prange Jr, 2010). Myxedema is associated with severe mental disorders including psychoses, sometimes called 'myxematous madness'. Depression related to hypothyroidism, even subclinical hypothyroidism may affect mood (Haggerty and Prange, 1995). Thyroid deficits are frequently observed in bipolar patients, especially in women with the rapid cycling form of the disease (Bauer et al., 2008). Both subclinical hypothyroidism and subclinical hyperthyroidism increase the risk for Alzheimer's disease, especially in women (Tan et al., 2008). However, most hypothyroid patients do not meet the criteria for a mental disorder. A recent study evaluated brain glucose metabolism during T4 treatment of hypothyroidism (Bunevičius and Prange Jr, 2010). A reduction in depression and cognitive symptoms was associated with restoration of metabolic activity in brain areas that are integral to the regulation of mood and cognition (Bauer et al., 2009). In hypothyroidism, replacement therapy with T4 remains the treatment of choice and resolves most physical and psychological signs and symptoms in most patients. However, some patients do not feel entirely well despite doses of T4 that are usually adequate (Saravanan et al., 2002). In T4-treated patients, it was found that reduced psychological well being is associated with occurrence of polymorphism in the D2 gene (Panicker et al., 2009), as well as in the OATP1c1 gene (van der Deure et al., 2008). Thyroid hormone replacement with a combination of T4 and T3, in comparison with T4 monotherapy, improves mental functioning in some but not all hypothyroid patients (Bunevicius et al., 1999; Nygaard et al., 2009), and most of the patients subjectively prefer combined treatment (Escobar-Morreale et al., 2005). It was concluded that future trials on thyroid hormone replacement should target genetic polymorphisms in deiodinase and thyroid hormone transporters (Wiersinga, 2009).

7. Hypothyroidism and development

7.1 Congenital hypothyroidism

Traditionally, research on the role of the thyroid hormones in brain development has focused on the postnatal phase and on identifying congenital hypothyroidism, which is the final result of the deficiency suffered throughout the pregnancy (Pérez-López, 2007). Iodine deficit during pregnancy produces an increase in perinatal mortality and low birth weight which can be prevented by iodated oil injections given in the latter half of pregnancy or in other supplementary forms (European Commission, 2002). The

epidemiological studies suggest that hypothyroxinemia, especially at the beginning of pregnancy, affects the neurological development of the new human being in the long term (Pérez-López, 2007). Full-scale clinical studies have demonstrated a correlation between maternal thyroid insufficiency during pregnancy and a low neuropsychological development in the neonate (Haddow et al., 1999). Maternal hypothyroxinemia during the first gestational trimester limits the possibilities of postnatal neurodevelopment (Pop et al., 2003; Kooistra et al., 2006). The most serious form of brain lesion corresponds to neurological cretinism, but mild degrees of maternal hypothyroxinemia also produce alterations in psychomotor development (Morreale de Escobar et al., 2004; Visser, 2006). The thyroid function of neonates at birth is significantly related to the brain size and its development during the first two years of life (Van Vliet, 1999). Screening programs for neonatal congenital hypothyroidism indicate that it is present in approximately one case out of 3000 to 4000 live births (Klein et al., 1991). Seventy-eight percent were found to have an intelligence quotient (IQ) of over 85 when congenital hypothyroidism was diagnosed within the first few months after birth, 19% when it was diagnosed between 3 and 6 months, and 0% when the diagnosis was made 7 months after birth (Pérez-López, 2007). In a meta-analysis of seven studies (Derksen-Lubsen and Verkerk, 1996), a decrease of 6.3 IQ points was found among neonates who suffered hypothyroidism during pregnancy in comparison to the control group. Long-term sequelae of hypothyroidism also affect intellectual development during adolescence. The affected children show an average of 8.5 IQ points less than the control group, with deficits in memory and in visuospatial and motor abilities related to the seriousness of congenital hypothyroidism and due to inadequate treatment in their early childhood (Rovet, 1999).

Untreated congenital hypothyroidism (sporadic cretinism) produces neurologic deficits having predominantly postnatal origins (Porterfield, 2000). Although mental retardation can occur, it typically is not as severe as that seen in neurologic cretinism. Untreated infants with severe congenital hypothyroidism can lose 3-5 IQ points per month if untreated during the first 6-12 months of life (Burrow et al., 1994). If the children are treated with thyroid hormones soon after birth, the more severe effects of thyroid deficiency are alleviated (Porterfield, 2000). However, these children are still at risk for mild learning disabilities. They may show subtle language, neuromotor, and cognitive impairment (Rovet et al., 1996). They are more likely to show attention deficit hyperactivity disorder (ADHD), have problems with speech and interpretation of the spoken word, have poorer fine motor coordination, and have problems with spatial perception (Rovet et al., 1992). The severity of these effects is correlated with the retardation of bone ossification seen at birth. This would suggest that the damage is correlated with the mild hypothyroidism they experience in utero. Rovet and Ehrlich (1995) have proposed that the sensitive periods for thyroid hormones vary for verbal and nonverbal skills. The critical period for verbal and memory skills appears to be in the first 2 months postpartum, whereas for visuospatial or visuomotor skills it is prenatal (Porterfield, 2000). Thyroid hormone deficiency impairs learning and memory, which depend on the structural integrity of the hippocampus (Porterfield, 2000). Maturation and synaptic development of the pyramidal cells of the hippocampus are particularly sensitive to thyroid hormone deficiency during fetal/perinatal development (Madeira et al., 1992). Early in fetal development (rats), thyroid hormone deficiency decreases radial glial cell maturation and therefore impairs cellular migration (Rami and Rabie, 1988), which can lead to irreversible changes in the

neuronal population and connectivity in this region. Animals with experimentally induced congenital hypothyroidism show delayed and decreased axonal and dendritic arborization in the cerebral cortex, a decrease in nerve terminals, delayed myelination, abnormal cochlear development, and impaired middle ear ossicle development (Porterfield and Hendrich, 1993).

7.2 Endemic cretinism

The most severe neurologic impairment resulting from a thyroid deficiency is an endemic cretinism caused by iodine deficiency (Porterfield, 2000). In fact, iodine deficiency represents the single most preventable cause of neurologic impairment and cerebral palsy in the world today (Donati et al., 1992; Morreale de Escobar et al., 1997). These individuals suffer from hypothyroidism that begins at conception because the dietary iodine deficiency prevents synthesis of normal levels of thyroid hormones (Porterfield, 2000). It is more severe than that seen in congenital hypothyroidism because the deficiency occurs much earlier in development and results in decreased brain thyroid hormone exposure both before and after the time the fetal thyroid gland begins functioning (Porterfield, 2000). Problems with endemic cretins include mental retardation that can be profound, spastic dysplasia, and problems with gross and fine motor control resulting from damage to both the pyramidal and the extrapyramidal systems (Porterfield, 2000). These problems include disturbances of gait, and in the more extreme forms, the individuals cannot walk or stand (Pharoah et al., 1981; Donati et al., 1992; Stanbury, 1997). If postnatal hypothyroidism is present, there is growth retardation and delayed or absent sexual maturation (Porterfield and Hendrich, 1993). Damage occurs both to structures such as the corticospinal system that develop relatively early in the fetus and structures such as the cerebellum that develop predominantly in the late fetal and early neonatal period (Porterfield, 2000). The damage is inversely related to maternal serum thyroxine (T4) levels but not to triiodothyronine (T3) levels (Calvo et al., 1990; Donati et al., 1992; Porterfield and Hendrich, 1993). Delong (1987) suggests that the neurologic damage occurs primarily in the second trimester, which is an important period for formation of the cerebral cortex, the extrapyramidal system, and the cochlea, areas damaged in endemic cretins. Maternal T3 levels are often normal and the mother therefore may not show any overt symptoms of hypothyroidism (Porterfield, 2000). Early development of the auditory system appears to be dependent upon thyroid hormones (Bradley et al., 1994). The greater impairment characterized by endemic cretinism relative to congenital hypothyroidism is thought to result from the longer period of exposure of the developing brain to hypothyroidism in endemic cretinism (Donati et al., 1992; Porterfield and Hendrich, 1993; Morreale de Escobar et al., 1997).

7.3 Thyroid function during pregnancy and iodine deficiency

Glinoeer and his group showed that, in conditions of mild iodine deficiency, the serum concentrations of free thyroxine decrease steadily and significantly during gestation (Glinoeer, 1997a,b). Although the median values remain within the normal range, one third of pregnant women have free thyroxine values near or below the lower limit of normal. This picture is in clear contrast with thyroid status during normal pregnancy and normal iodine intake, which is characterised by only a slight (15%) decrease of free thyroxine by the end of gestation. After an initial blunting of serum thyroid stimulating hormone (TSH) caused by increased

concentrations of human chorionic gonadotrophin, serum TSH concentrations increase progressively in more than 80% of pregnant Belgian women, although these levels also remain within the normal range. This change is accompanied by an increase in serum thyroglobulin, which is directly related to the increase in TSH. This situation of chronic thyroid hyperstimulation results in an increase in thyroid volume by 20% to 30% during gestation, a figure twice as high as that in conditions of normal iodine supply. The role of the lack of iodine in the development of these different anomalies is indicated by the fact that a daily supplementation with physiological doses of iodine (150 µg/day) prevents their occurrence (Glinoyer et al., 1995). In moderate iodine deficiency, the anomalies are of the same nature but more marked. For example, in an area of Sicily with an iodine intake of 40 µg/day, Vermiglio et al reported a decline of serum free thyroxine of 31% and a simultaneous increase of serum TSH of 50% during early (8th to 19th weeks) gestation (Vermiglio et al., 1995). Only a limited number of studies are available on thyroid function during pregnancy in populations with severe iodine deficiency (iodine intake below 25 µg iodine/day). Moreover, because of the extremely difficult conditions in which these studies were performed, the results are necessarily only partial. The most extensive data are available from New Guinea (Choufoer et al., 1965; Pharoah et al., 1984) and the Democratic Republic of Congo (DRC, formerly Zaire) (Thilly et al., 1978; Delange et al., 1982). The studies conducted in such environments show that the prevalence of goitre reaches peak values of up to 90% in females of child bearing age 20 and that during pregnancy, serum thyroxine is extremely low and serum TSH extremely high. However, it has been pointed out that for a similar degree of severe iodine deficiency in the DRC and New Guinea, serum thyroxine in pregnant mothers is much higher in the DRC (103 nmol/l) than in New Guinea (38.6–64.4 nmol/l) (Morreale de Escobar et al., 1997). The frequency of values below 32.2 nmol/l is only 3% in the DRC while it is 20% in New Guinea. This discrepancy was understood only when it was demonstrated that in the DRC, iodine deficiency is aggravated by selenium deficiency and thiocyanate overload (see later section) (Delange et al., 1982; Vanderpas et al., 1990; Contempre et al., 1991). Also, during pregnancy, iodine deficiency produces hypothyroxinemia which consequently causes (1) thyroid stimulation through the feedback mechanisms of TSH, and (2) goitrogenesis in both mother and fetus (Pérez-López, 2007). For this reason, it seems that moderate iodine deficiency causes an imbalance in maternal thyroid homeostasis, especially toward the end of pregnancy, leading to isolated hypothyroxinemia suggestive of biochemical hypothyroidism. Uncontrolled hypothyroidism in pregnancy can lead to preterm birth, low birth weight and mental retardation (Drewns and Seremak-Mrozikiewicz, 2011).

7.4 Perinatal thyroid function and iodine deficiency

In mild iodine deficiency, serum concentrations of TSH and thyroglobulin are still higher in neonates than in mothers (Glinoyer, 1997a,b), indicating that neonates are more sensitive than adults to the effects of iodine deficiency. Again, the role of iodine deficiency is demonstrated by the fact that neonates born to mothers who have been supplemented with iodine during pregnancy have a lower thyroid volume and serum thyroglobulin and higher urinary iodine than newborns born to untreated mothers (Glinoyer et al., 1995). Other evidence of chronic TSH overstimulation of the neonatal thyroid is the fact that there is a slight shift towards increased values of the frequency distribution of neonatal TSH on day 5, which is the time of systematic screening for congenital hypothyroidism (Delange, 2001). The frequency of values above 5

mU/l blood is 4.5%, while the normal value is below 3%. In moderate iodine deficiency, the anomalies are of the same nature but more drastic than in conditions of mild iodine deficiency (Delange, 2001). Transient hyperthyrotrophinaemia or even transient neonatal hypothyroidism can occur. The frequency of the latter condition is approximately six times higher in Europe than in the United States where the iodine intake is much higher (Delange et al., 1983). The shift of neonatal TSH towards increased values is more marked and the frequency of values above 20–25 mU/l blood, that is above the cut off point used for recalling the neonates because of suspicion of congenital hypothyroidism in programmes of systematic screening for congenital hypothyroidism, is increased (Delange, 2001). There is an inverse relationship between the median urinary iodine of populations of neonates used as an index of their iodine intake and the recall rate at screening (Delange, 1994 & 1998). It has to be pointed out that these changes in neonatal TSH frequently occur for levels of iodine deficiency that would not affect the thyroid function in non-pregnant adults (Delange, 2001). The hypersensitivity of neonates to the effects of iodine deficiency is explained by their very small intrathyroidal iodine pool, which requires increased TSH stimulation and a fast turnover rate in order to maintain normal secretion of thyroid hormones (Delange, 1998). In severe iodine deficiency, as in the mothers, the biochemical picture of neonatal hypothyroidism is caricatural, especially in the DRC where mean cord serum thyroxine and TSH concentrations are 95.2 nmol/l and 70.7 mU/l respectively and where as many as 11% of the neonates have both a cord serum TSH above 100 mU/l and a cord thyroxine below 38.6 nmol/l, that is a biochemical picture similar to the one found in thyroid agenesis (Delange et al., 1993).

7.5 Hypothyroidism and brain development in humans

The neonatal period of development in humans is known to be sensitive to thyroid hormone, especially as revealed in the disorder known as congenital hypothyroidism (CH) (Krude et al., 1977; Dussault and Walker, 1983; Miculan et al., 1993; Foley, 1996; Kooistra et al., 1994; van Vliet, 1999; Rovet, 2000). CH occurs at a rate of approximately 1 in 3,500 live births (Delange, 1997). Because CH infants do not present a specific clinical picture early, their diagnosis based solely on clinical symptoms was delayed before neonatal screening for thyroid hormone (Zoeller et al., 2002). In fact, only 10% of CH infants were diagnosed within the first month, 35% within 3 months, 70% within the first year, and 100% only after age 3 (Alm et al., 1984). The intellectual deficits as a result of this delayed diagnosis and treatment were profound. One meta-analysis found that the mean full-scale intelligence quotient (IQ) of 651 CH infants was 76 (Klein, 1980). Moreover, the percentage of CH infants with an IQ above 85 was 78% when the diagnosis was made within 3 months of birth, 19% when it was made between 3 and 6 months, and 0% when diagnosed after 7 months of age (Klein, 1980; Klein and Mitchell, 1996). Studies now reveal that the long-term consequences of CH are subtle if the diagnosis is made early and treatment is initiated within 14 days of birth (Mirabella et al., 2000; Hanukoglu et al., 2001; Leneman et al., 2001), which can be accomplished only by mandatory screening for thyroid function at birth. This medical profile has become the principal example illustrating the importance of thyroid hormone for normal brain development (Zoeller et al., 2002). Recent studies indicate that thyroid hormone is also important during fetal development. Thyroid hormones are detected in human coelomic and amniotic fluids as early as 8 weeks of gestation, before the onset of fetal thyroid function at 10–12 weeks (Contempre et al., 1993). In addition, human fetal brain tissues express thyroid hormone receptors (TRs), and receptor occupancy by thyroid

hormone is in the range known to produce physiological effects as early as 9 weeks of gestation (Ferreiro et al., 1988). Finally, the mRNAs encoding the two known TR classes exhibit complex temporal patterns of expression during human gestation (Iskaros et al., 2000), and the mRNAs encoding these TR isoforms are expressed in the human oocyte (Zhang et al., 1997). These data indicate that maternal thyroid hormone is delivered to the fetus before the onset of fetal thyroid function, and that the minimum requirements for thyroid hormone signaling are present at this time (Zoeller et al., 2002). Two kinds of pathological situations reveal the functional consequences of deficits in thyroid hormone during fetal development (Zoeller et al., 2002). The first is that of cretinism, a condition usually associated with severe iodine insufficiency in the diet (Delange, 2000). There are two forms of cretinism based on clinical presentation: neurological cretinism and myxedematous cretinism (Delange, 2000). Neurological cretinism is characterized by extreme mental retardation, deaf-mutism, impaired voluntary motor activity, and hypertonia (Delange, 2000). In contrast, myxedematous cretinism is characterized by less severe mental retardation and all the major clinical symptoms of persistent hypothyroidism (Delange, 2000). Iodide administration to pregnant women in their first trimester eliminates the incidence of neurological cretinism (Zoeller et al., 2002). However, the initiation of iodine supplementation by the end of the second trimester does not prevent neurological damage (Cao et al., 1994; Delange, 2000). Several detailed studies of endemias occurring in different parts of the world have led to the proposal that the various symptoms of the two forms of cretinism arise from thyroid hormone deficits occurring at different developmental windows of vulnerability (Cao et al., 1994; Delange, 2000). Therefore, thyroid hormone appears to play an important role in fetal brain development, perhaps before the onset of fetal thyroid function (Zoeller et al., 2002). The second type of pathological situation is that of subtle, undiagnosed maternal hypothyroxinemia (Zoeller et al., 2002). The concept and definition of maternal hypothyroxinemia were developed in a series of papers by Man et al. (Man and Jones, 1969; Man and Serunian, 1976; Man and Brown, 1991). Low thyroid hormone was initially defined empirically - those pregnant women with the lowest butanol-extractable iodine among all pregnant women (de Escobar et al., 2000). This work was among the first to document an association between subclinical hypothyroidism in pregnant women and neurological function of the offspring. After the development of radioimmunoassay for thyroid hormone, Pop et al. (1995) found that the presence of antibodies to thyroid peroxidase in pregnant women, independent of thyroid hormone levels per se, is associated with significantly lower IQ in the offspring. Subsequent studies have shown that children born to women with thyroxine (T₄) levels in the lowest 10th percentile of the normal range had a higher risk of low IQ and attention deficit (Haddow et al., 1999). Excellent recent reviews discuss these studies in detail (de Escobar et al., 2000). Taken together, these studies present strong evidence that maternal thyroid hormone plays a role in fetal brain development before the onset of fetal thyroid function, and that thyroid hormone deficits in pregnant women can produce irreversible neurological effects in their offspring (Gupta et al., 1995; Klett, 1997).

7.6 Hypothyroidism and brain development in experimental animals

Considerable research using experimental animals has provided important insight into the mechanisms and consequences of thyroid hormone action in brain development (Zoeller et al., 2002). The body of this work is far too extensive to review here but has been reviewed at critical times during the past 50 years (de Escobar et al., 2000; Oppenheimer et al., 1994;

Oppenheimer and Schwartz, 1997; Pickard et al., 1997). Several themes have emerged that provide a framework in which to begin to understand the role of thyroid hormone in brain development. First, the majority of biological actions of thyroid hormone appear to be mediated by TRs, which are ligand-dependent transcription factors (Mangelsdorf et al., 1995). There are two genes, encoding TR α and TR β , although these two receptors do not exhibit different binding characteristics for T4 and for triiodothyronine (T3) (Zoeller et al., 2002). Second, based on considerable work in the cerebellum, there appear to be critical periods of thyroid hormone action during development. As originally defined (Brown et al., 1939), the critical period was that developmental stage where thyroid hormone replacement to CH children could improve their intellectual outcome. This definition was also applied to experimental studies to identify the developmental period during which thyroid hormone exerts a specific action (Zoeller et al., 2002). It is now generally accepted that there is no single critical period of thyroid hormone action on brain development, either in humans (Delange, 2000) or in animals (Dowling et al., 2000). Rather, thyroid hormone acts on a specific development process during the period that the process is active. For example, thyroid hormone effects on cellular proliferation would necessarily be limited to the period of proliferation for a specific brain area. Because cells in different brain regions are produced at different times (Bayer and Altman, 1995), the critical period for thyroid hormone action on cell proliferation would differ for cells produced at different times.

7.7 Thyroid hormone deficiency and neuronal development

Thyroid hormone deficiency during a critical developmental period can impair cellular migration and development of neuronal networks. Neuronal outgrowth and cellular migration are dependent on normal microtubule synthesis and assembly and these latter processes are regulated by thyroid hormones (Nunez et al., 1991). During cerebral development, postmitotic neurons forming near the ventricular surface must migrate long distances to reach their final destination in the cortical plate where they form a highly organized 6-layer cortical structure (Porterfield, 2000). Appropriate timing of this migration is essential if normal connectivity is to be established. This migration depends not only upon specialized cells such as the radial glial cells that form a scaffolding system but also on specific adhesion molecules in the extracellular matrix that are associated with the focal contacts linking migrating neurons with radial glial fibers (Mione and Parnavelas, 1994). These neurons migrate along radial glial fibers, and following neuronal migration, the radial glial cells often degenerate or become astrocytes (Rakic, 1990). Migration also depends on adhesive interactions involving extracellular matrix proteins such as laminin and the cell-surface receptor integrin (Porterfield, 2000). Disorders of neuronal migration are considered to be major causes of both gross and subtle brain abnormalities (Rakic, 1990). Hypothyroidism during fetal and neonatal development results in delayed neuronal differentiation and decreased neuronal connectivity (Nunez et al., 1991).

8. References

- Ahmed OM, El-Gareib, AW, El-bakry, AM, Abd El-Tawab, S.M, Ahmed, RG. Thyroid hormones states and brain development interactions. *Int J Devl Neurosc* 2008; 26: 147-209.

- Alm J, Hagenfeldt L, Larsson A, Lundberg K. Incidence of congenital hypothyroidism: retrospective study of neonatal laboratory screening versus clinical symptoms as indicators leading to diagnosis. *Br Med J* 1984; 289: 1171-1175.
- Aminoff MJ. *Neurology and General Medicine: Expert Consult: Online and Print*. Edinburgh: Churchill Livingstone, 2007.
- Bauer M, Goetz T, Glenn T, Whybrow PC. The thyroid-brain interaction in thyroid disorders and mood disorders. *J Neuroendocrinol* 2008; 20: 1101-1114.
- Bauer M, Silverman DH, Schlagenhaut F, et al. Brain glucose metabolism in hypothyroidism: a positron emission tomography study before and after thyroid hormone replacement therapy. *J Clin Endocrinol Metab* 2009; 94: 2922-2929.
- Bayer SA, Altman J. Neurogenesis and neuronal migration. In: *The Rat Nervous System*, 2nd ed. (Paxinos G, ed). San Diego, CA:Academic Press, 1995; 1079-1098.
- Bradley DJ, Towle HC, Young WS III. α and β thyroid hormone receptor (TR) gene expression during auditory neurogenesis: evidence for TR isoform-specific transcriptional regulation in vivo. *Proc Natl Acad Sci USA* 1994; 91:439-443.
- Brown AW, Bronstein IP, Kraines R. Hypothyroidism and cretinism in childhood. VI. Influence of thyroid therapy on mental growth. *Am J Dis Child* 1939; 57:517-523.
- Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. *N Engl J Med* 1999; 340: 424-429.
- Bunevičius, R., Prange, A.J. Thyroid disease and mental disorders: cause and effect or only comorbidity? *Current Opinion in Psychiatry* 2010; 23: 363-368.
- Burrow, GN, Fisher, DA, Larsen, PR. Maternal and fetal thyroid function. *N Engl J Med* 1994; 331:1072-1078.
- Calvo R, Obregon MJ, Ruiz de Ona C, Escobar del Rey F, Morreale de Escobar G. Congenital hypothyroidism as studied in rats. *J Clin Invest* 1990; 86:889-899.
- Cao XY, Jiang XM, Dou ZH, Murdon AR, Zhang ML, O'Donnell K, Ma T, Kareem A, DeLong N, Delong GR. Timing of vulnerability of the brain to iodine deficiency in endemic cretinism. *N Engl J Med* 1994; 331:1739-1744.
- Choufoer JC, Van Rhijn M, Querido A. Endemic goiter in western New Guinea. II. Clinical picture, incidence and pathogenesis of endemic cretinism. *J Clin Endocrinol Metab* 1965; 25: 385-402.
- Contempre B, Dumont JE, Bebe N, et al. Effect of selenium supplementation in hypothyroid subjects of an iodine and selenium deficient area: the possible danger of indiscriminate supplementation of iodine deficient subjects with selenium. *J Clin Endocrinol Metab* 1991; 73: 213-15.
- Contempre B, Jauniaux E, Calvo R, Jurkovic D, Campbell S, de Escobar GM. Detection of thyroid hormones in human embryonic cavities during the first trimester of pregnancy. *J Clin Endocrinol Metab* 1993; 77:1719-1722.
- de Escobar GM, Obregon MJ, Escobar del Rey F. Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia? *J Clin Endocrinol Metab* 2000; 85: 3975-3987.
- Delange F, Bourdoux P, Ketelbant-Balasse P, et al. Transient primary hypothyroidism in the newborn. In: Dussault JH, Walker P, eds. *Congenital hypothyroidism*. New York: M Dekker, 1983; 275-301.

- Delange F, Bourdoux P, Laurence M, et al. Neonatal thyroid function in iodine deficiency. In: Delange F, Dunn JT, Glinoe D, eds. *Iodine deficiency in Europe. A continuing concern*. New York: Plenum Press, 1993; 199-210.
- Delange F, Thilly C, Bourdoux P, et al. Influence of dietary goitrogens during pregnancy in humans on thyroid function of the newborn. In: Delange F, Iteke FB, Ermans AM, eds. *Nutritional factors involved in the goitrogenic action of cassava*. Ottawa: International Development Research Centre, 1982; 40-50.
- Delange F. Neonatal screening for congenital hypothyroidism: results and perspectives. *Horm Res* 1997; 48:51-61.
- Delange F. Screening for congenital hypothyroidism used as an indicator of the degree of iodine deficiency and of its control. *Thyroid* 1998; 8: 1185-92.
- Delange F. The disorders induced by iodine deficiency. *Thyroid* 1994; 4: 107-128.
- Delange FM. Endemic cretinism. In: Werner and Ingbar's *The Thyroid: A Fundamental and Clinical Text*, 8th ed. (Braverman LE, Utiger RD, eds). Philadelphia:Lippincott Williams and Wilkins, 2000; 743-754.
- Delange, F. Iodine deficiency as a cause of brain damage. *Postgrad Med J* 2001; 77: 217-220.
- DeLong GR, Ma T, Cao XY, Jiang XM, Dou ZH, Murdon AR, Zhang ML, Heinz ER. The neuromotor deficit in endemic cretinism. In: *The Damaged Brain of Iodine Deficiency* (Stanbury JB, ed). New York:Cognizant Communications, 1994; 9-17.
- DeLong R. Neurological involvement in iodine deficiency disorders. In: *The Prevention and Control of Iodine Deficiency Disorders* IHetzel BS, Dunn JT, Stanbury JB, eds). Amsterdam:Elsevier, 1987;49-63.
- Derksen-Lubsen G, Verkerk PH. Neuropsychologic development in early treated congenital hypothyroidism: analysis of literature data. *Pediatric Res* 1996; 39: 561-566.
- Donati 1, Antonelli A, Bertoni F, Moscogiuri D, Andreani M, Venturi S, Filippi T, Gasperinin 1, Neri S, Baschieri L. Clinical picture of endemic cretinism in central Apennines (Montefeltro). *Thyroid* 1992; 2:283-290.
- Dowling ALS, Martz GU, Leonard JL, Zoeller RT. Acute changes in maternal thyroid hormone induce rapid and transient changes in specific gene expression in fetal rat brain. *J Neurosci* 2000; 20: 2255-2265.
- Drews K, Seremak-Mrozikiewicz A. The Optimal Treatment of Thyroid Gland Function Disturbances During Pregnancy. *Curr Pharm Biotechnol*. 2011 Feb 22. [Epub ahead of print].
- Dussault JH, Walker P. *Congenital Hypothyroidism*. New York:Marcel Dekker, 1983.
- Elizabeth DA, Agabegi, SS. *Step-Up to Medicine (Step-Up Series)*. Hagerstown, MD. Lippincott Williams & Wilkins, 2008.
- Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G. Review: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. *J Clin Endocrinol Metab* 2005; 90: 4946-4954.
- European Commission, Health & Consumer Protection Directorate-General. Opinion of the Scientific Committee on Food on the tolerable upper intake level of iodine. SCF/CS/NUT/UPPLEV/26 Final. Brussels: European Union, 2002. pp 1-25.
- Ferreiro B, Bernal J, Goodyer CG, Branchard CL. Estimation of nuclear thyroid hormone receptor saturation in human fetal brain and lung during early gestation. *J Clin Endocrinol Metab* 1988; 67:853-856.

- Foley TP. Congenital hypothyroidism. In: Werner and Ingbar's *The Thyroid*, 7th ed. (Braverman LE, Utiger RD, eds). Philadelphia:Lippincott-Raven, 1996; 988-994.
- Glinoe D, De Nayer P, Delange F, et al. A randomized trial for the treatment of excessive thyroid stimulation in pregnancy: maternal and neonatal effects. *J Clin Endocrinol Metab* 1995; 80: 258-69.
- Glinoe D. Maternal and fetal impact of chronic iodine deficiency. *Clin Obstet Gynecol* 1970a; 40: 102-16.
- Glinoe D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. *Endocr Rev* 1970b; 18: 404-33.
- Grueters A, Biebertmann H, Krude H. Molecular pathogenesis of congenital hypothyroidism, 2002; September, No. 4 (www.hotthyroidology.com).
- Gull WW. On a cretinoid state supervening in adult life in women. *Trans Clin Soc London* 1874; 7: 180.
- Gupta RK, Bhatia V, Poptani H, Gujral RB. Brain metabolite changes on *in vivo* proton magnetic resonance spectroscopy in children with congenital hypothyroidism. *J Pediatr* 1995; 126:389-392.
- Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med* 1999; 341: 549-555.
- Haddow JE, Palomaki GE, Allen WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med* 1999; 341:549-555.
- Haggerty JJ Jr, Prange AJ Jr. Borderline hypothyroidism and depression. *Annu Rev Med* 1995; 46: 37-46.
- Hanukoglu A, Perlman K, Shamis I, Brnjac L, Rovet J, Daneman D. Relationship of etiology to treatment in congenital hypothyroidism. *J Clin Endocrinol Metab* 2001; 86:186-191.
- Harper M, Seifert EL. Thyroid Economy—Regulation, Cell Biology, Thyroid Hormone Metabolism and Action: The Special Edition: Metabolic Effects of Thyroid Hormones Thyroid Hormone Effects on Mitochondrial Energetics. *Thyroid* 2008; 18 (2): 145-156.
- Hoch FL. Lipids and thyroid hormones. *Prog Lipid Res* 1988; 27: 199-270.
- Hoch FL. Biochemistry of hyperthyroidism and hypothyroidism. *Postgrad Med J* 1968; 44:347-362.
- Iskaros J, Pickard M, Evans I, Sinha A, Hardiman P, Ekins R. Thyroid hormone receptor gene expression in first trimester human fetal brain. *J Clin Endocrinol Metab* 2000; 85:2620-2623.
- Klein R. History of congenital hypothyroidism. In: *Neonatal Thyroid Screening* (Burrow GN, Dussault JH, eds). New York:Raven Press, 1980; 51-59.
- Klein RZ, Haddow JE, Faix JD, Brown RS, Hermos RJ, Pulkkinen A, Mitchell ML. Prevalence of thyroid deficiency in pregnant women. *Clin Endocrinol (Oxf)* 1991; 35: 41-46.

- Klein RZ, Mitchell ML. Neonatal screening for hypothyroidism. In: Werner and Ingbar's *The Thyroid*, 7th ed. (Braverman LE, Utiger RD, eds). Philadelphia: Lippincott-Raven, 1996;984-988.
- Klett M. Epidemiology of congenital hypothyroidism. *Exp Clin Endocrinol Diabetes* 1997; 105 (suppl 4):19-23.
- Kocher T. Ueber Kropfexstirpation und ihre Folgen. *Arch Klin Chir* 1983; 29:254.
- Kooistra L, Crawford S, van Baar AL, Brouwers EP, Pop VJ. Neonatal effects of maternal hypothyroxinemia during early pregnancy. *Pediatrics* 2006; 117: 161-167.
- Kooistra L, Laane C, Vulsma T, Schellekens JMH, van der Meere JJ, Kalverboer AF. Motor and cognitive development in children with congenital hypothyroidism. *J Pediatr* 1994; 124:903-909.
- Krude H, Biebermann H, Krohn HP, Gruters A. Congenital hyperthyroidism. *Exp Clin Endocrinol Diabetes* 1977; 105:6-11.
- Laker ME, Mayes PA. Effect of hyperthyroidism and hypothyroidism on lipid and carbohydrate metabolism of the perfused rat liver. *Biochem J* 1981; 196: 247-255
- Lania A, Persani L, Beck-Peccoz P. Central hypothyroidism. *Pituitary* 2008; 11(2):181-6.
- Leneman M, Buchanan L, Rovet J. Where and what visuospatial processing in adolescents with congenital hypothyroidism. *J Int Neuropsychol Soc* 2001; 7:556-562.
- Madeira MD, Sousa N, Lima-Andrade MT, Calheiros F, Cadete-Leite A, Paula-Barbosa MM. Selective vulnerability of the hippocampal pyramidal neurons to hypothyroidism in male and female rats. *J Comp Neurol* 1992; 322:501-518.
- Man EB, Brown JF, Serunian SA. Maternal hypothyroxinemia: psychoneurological deficits of progeny. *Ann Clin Lab Sci* 1991; 21:227-239.
- Man EB, Jones WS. Thyroid function in human pregnancy. Part V. *Am J Obstet Gynecol* 1969; 104:898-908.
- Man EB, Serunian SA. Thyroid function in human pregnancy. IX: Development or retardation of 7-year-old progeny of hypothyroxinemic women. *Am J Obstet Gynecol* 1976; 125:949.
- Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. *Cell* 1995; 83:841-850.
- Miculan J, Turner S, Paes BA. Congenital hypothyroidism: diagnosis and management. *Neonatal Netw* 1993; 12:25-34.
- Mione MC, Parnavelas JG. How do developing cortical neurons know where to go? *Trends Neurosci* 1994; 17:443-445.
- Mirabella G, Feig D, Astzalos E, Perlman K, Rovet JF. The effect of abnormal intrauterine thyroid hormone economies on infant cognitive abilities. *J Pediatr Endocrinol Metab* 2000; 13:191-194.
- Morreale de Escobar G, Obregón MJ, Escobar del Rey F. Role of thyroid hormone during early brain development. *Eur J Endocrinol* 2004; 151(Suppl 3): U25-U37.
- Morreale de Escobar G, Obregon MJ, Calvo R, Pedraza P, Escobar del Rey F. Iodine deficiency, the hidden scourge: the rat model of human neurological cretinism. In: *Recent Research Developments in Neuroendocrinology* (Hendrich CE, ed). Kerala State, India: Research Signpost, 1997; 55-70.
- Nunez J, Couchie D, Aniello F, Bridoux AM. Regulation by thyroid hormone of microtubule assembly and neuronal differentiation. *Neurochem Res* 1991; 16: 975-982

- Nygaard B, Jensen E, Kvetny J, et al. Effect of combination therapy with thyroxine (T4) and 3,5,3-triiodothyronine (T3) versus T4 monotherapy in patients with hypothyroidism, a double blind, randomized cross-over study. *Eur J Endocrinol* 2009; 161: 895-902.
- Onputtha DC. Effects of Hypothyroidism on the Body, 2010. *EzineArticles.com*.
- Oppenheimer JH, Schwartz HL, Strait KA. Thyroid hormone action 1994: the plot thickens. *Eur J Endocrinol* 1994; 130:15-24.
- Oppenheimer JH, Schwartz HL. Molecular basis of thyroid hormone-dependent brain development. *Endocr Rev* 1997; 18:462-475.
- Ord WM. On myxedema, a term proposed to be applied to an essential condition in the "cretinoid" affection occasionally observed in middle-aged women. *Medico-Chir Trans* 1978; 61: 57.
- Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. *J Clin Endocrinol Metab* 2009; 94: 1623-1629.
- Pérez-López, F.R.. Iodine and thyroid hormones during pregnancy and postpartum. *Gynecological Endocrinology*, 2007; 23(7): 414-428.
- Pharoah P, Connolly K, Hetzel B, Ekins R. Maternal thyroid function and motor competence in the child. *Dev Med Child Neurol* 1981; 23: 76-82.
- Pharoah POD, Connolly KJ, Ekins RP, et al. Maternal thyroid hormone levels in pregnancy and the subsequent cognitive and motor performance of the children. *Clin Endocrinol (Oxf)* 1984; 21: 265-70.
- Pickard MR, Evans IM, Bandopadhyay R, Leonard AJ, Sinha AK, Ekins RP. Thyroid hormone action in rat brain from fetal to adult life. In: *Recent Research Developments in Neuroendocrinology—Thyroid Hormone and Brain Maturation* (Hendrich CE, ed). Research SignPost, 1997; 15-29.
- Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL, de Vijlder JJ. Maternal hypothyroxinemia during early pregnancy and subsequent child development: a 3-year follow-upstudy. *Clin Endocrinol (Oxf)* 2003; 59: 282-288.
- Pop VJ, de Vries E, van Baar AL, Waelkens JJ, de Rooy HA, Horsten M, Donkers MM, Komproe IH, van Son MM, Vander HL. Maternal thyroid peroxidase antibodies during pregnancy: a marker of impaired child development? *J Clin Endocrinol Metab* 1995; 80: 3560-3566.
- Potemkin V. *Endocrinology*. Russian edition, Mir publishers, Moscow, 1989.
- Porterfield SP, Hendrich CE. The role of thyroid hormones in prenatal and neonatal neurological development-current perspectives. *Endocr Rev* 1993; 14:94-106.
- Porterfield, S.P. Thyroidal Dysfunction and Environmental Chemicals Potential Impact on Brain Development. - *Environ Health Perspect* 2000; 108(suppl 3): 433-438.
- Rakic P. Principles of neural cell migration. *Experientia* 1990; 46:882-891.
- Rami A, Rabie A. Effect of thyroid deficiency on the development of glia in the hippocampal formation of the rat: an immunocytochemical study. *GLIA* 1988; 1:337-345.
- Report of a Committee of the Clinical Society of London to Investigate the Subject of Myxedema. London, Longmans. Green & Co. Ltd. 1888.

- Reverdin JL: In discussion. Société médicale de Genève. Rev Med Suisse Romande 1882; 2: 537.
- Roberts CGP, Ladenson PW. Hypothyroidism. Lancet 2004; 363 (9411): 793–831.
- Rovet J, Ehrlich R, Altmann D. Psychoeducational outcome in children with early-treated congenital hypothyroidism. American Thyroid Association, 1996.
- Rovet JF, Ehrlich Rm, Sorbara DL. Neurodevelopment in infants and preschool children with congenital hypothyroidism: etiological and treatment factors affecting outcome. J Pediatr Psychol 1992; 2: 187-213.
- Rovet JF, Ehrlich RM. Long-term effects of L-thyroxine therapy for congenital hypothyroidism. J Pediatr 1995; 126:380-386.
- Rovet JF. Congenital hypothyroidism: long-term outcome. Thyroid 1999; 9: 741–748.
- Rovet JF. Neurobehavioral consequences of congenital hypothyroidism identified by newborn screening. In: Therapeutic Outcome of Endocrine Disorders (Stabler B, Bercu BB, eds). New York:Springer-Verlag, 2000; 235–254.
- Saravanan P, Chau WF, Roberts N, et al. Psychological well being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community based questionnaire study. Clin Endocrinol (Oxf) 2002; 57: 577–585.
- Simon H. "Hypothyroidism". University of Maryland Medical Center, 2006. University of Maryland Medical System, 22 S. Greene Street, Baltimore, MD 21201.
- Stanbury JB. The pathogenesis of endemic cretinism. J Endocrinol Invest 1997; 7: 409-419.
- Tan ZS, Beiser A, Vasan RS, et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med 2008; 168: 1514–1520.
- Thilly CH, Delange F, Lagasse R, et al. Fetal hypothyroidism and maternal thyroid status in severe endemic goiter. J Clin Endocrinol Metab 1978; 47: 354–60.
- Thomas, PF. Hypothyroidism. Pediatrics in Review 2004; 25 (3): 94-100.
- van der Deure WM, Appelhof BC, Peeters RP, et al. Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clin Endocrinol (Oxf) 2008; 69: 804–811.
- Van Vliet G. Neonatal hypothyroidism: treatment and outcome. Thyroid 1999; 9: 79–84.
- Vanderpas JB, Contempre B, Duale NL, et al. Iodine and selenium deficiency associated with cretinism in northern Zaire. Am J Clin Nutr 1990; 52: 1087–93.
- Vanderpump MPJ. Epidemiology of Thyroid Dysfunction - Hypothyroidism and Hyperthyroidism. Thyroid International 2009; 2: 1-12.
- Vanderpump MPJ. The epidemiology of thyroid diseases. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. 9th edn, 2005; pp 398-406. JB Lippincott-Raven, Philadelphia.
- Vermiglio F, Lo Presti VP, Scaffidi Argentina G, et al. Maternal hypothyroxinemia during the first half of gestation in an iodine deficient area with endemic cretinism and related disorders. Clin Endocrinol (Oxf) 1995; 42: 409–415.
- Visser TJ. The elemental importance of sufficient iodine intake: a trace is not enough. Endocrinology 2006; 147: 2095–2097.
- Wiersinga WM. Adult hypothyroidism. In: Thyroid Gland and its Diseases. Thyroid disease manager organization, 2010.
- Wiersinga WM. Do we need still more trials on T4 and T3 combination therapy in hypothyroidism? Eur J Endocrinol 2009; 161: 955–959.

- Zhang SS, Carrillo AJ, Darling DS. Expression of multiple thyroid hormone receptor mRNAs in human oocytes, cumulus cells, and granulosa cells. *Mol Hum Reprod* 1997; 3: 555-562.
- Zoeller, R.T., A.L.S. Dowling, Herzig, C.T.A., Iannacone, E.A., Gauger, K.J., Bansal, R. Thyroid Hormone, Brain Development, and the Environment. *Environ Health Perspect* 2002; 110(suppl 3): 355-361.